149 related articles for article (PubMed ID: 11957260)
1. Expression of oestrogen and progesterone receptors, Ki-67, p53 and BCL-2 proteins, cathepsin D, urokinase plasminogen activator and urokinase plasminogen activator-receptors in carcinomas of the female breast in an African population.
Mbonde MP; Amir H; Akslen LA; Kitinya JN
East Afr Med J; 2001 Jul; 78(7):360-5. PubMed ID: 11957260
[TBL] [Abstract][Full Text] [Related]
2. Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors.
Jahkola T; Toivonen T; von Smitten K; Virtanen I; Wasenius VM; Blomqvist C
Br J Cancer; 1999 Apr; 80(1-2):167-74. PubMed ID: 10389993
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of p53 and urokinase-type plasminogen activator in node-negative human breast cancers.
Peyrat JP; Vanlemmens L; Fournier J; Huet G; Révillion F; Bonneterre J
Clin Cancer Res; 1998 Jan; 4(1):189-96. PubMed ID: 9516970
[TBL] [Abstract][Full Text] [Related]
4. Cytological evaluation of biological prognostic markers from primary breast carcinomas.
Makris A; Allred DC; Powles TJ; Dowsett M; Fernando IN; Trott PA; Ashley SE; Ormerod MG; Titley JC; Osborne CK
Breast Cancer Res Treat; 1997 May; 44(1):65-74. PubMed ID: 9164679
[TBL] [Abstract][Full Text] [Related]
5. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer.
Foekens JA; Look MP; Peters HA; van Putten WL; Portengen H; Klijn JG
J Natl Cancer Inst; 1995 May; 87(10):751-6. PubMed ID: 7563153
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer.
Foekens JA; Schmitt M; van Putten WL; Peters HA; Kramer MD; Jänicke F; Klijn JG
J Clin Oncol; 1994 Aug; 12(8):1648-58. PubMed ID: 8040677
[TBL] [Abstract][Full Text] [Related]
7. Expression of estrogen and progesterone receptors in carcinomas of the female breast in Tanzania.
Mbonde MP; Amir H; Schwartz-Albiez R; Akslen LA; Kitinya JN
Oncol Rep; 2000; 7(2):277-83. PubMed ID: 10671671
[TBL] [Abstract][Full Text] [Related]
8. [Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma].
Göhring UJ; Scharl A; Ahr A
Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):177-83. PubMed ID: 8682282
[TBL] [Abstract][Full Text] [Related]
9. Differences in oestrogen and progesterone receptors, HER-2, p53 expression and proliferation in ductal breast cancers in relation to histopathological grade.
Zasławski R; Surowiak P; Paluchowski P; Dziegiel P; Maciejczyk A; Pudełko M; Wojnar A; Zabel M
Folia Morphol (Warsz); 2005 Feb; 64(1):9-15. PubMed ID: 15832264
[TBL] [Abstract][Full Text] [Related]
10. Urokinase plasminogen activator system gene expression is increased in human breast carcinoma and its bone metastases--a comparison of normal breast tissue, non-invasive and invasive carcinoma and osseous metastases.
Fisher JL; Field CL; Zhou H; Harris TL; Henderson MA; Choong PF
Breast Cancer Res Treat; 2000 May; 61(1):1-12. PubMed ID: 10930085
[TBL] [Abstract][Full Text] [Related]
11. p53 protein expression and oestrogen and progesterone receptor status in invasive ductal breast carcinomas.
Ioakim-Liossi A; Karakitsos P; Markopoulos C; Aroni K; Athanassiadou P; Delivelioti K; Athanassiades P; Vaiopoulos G
Cytopathology; 2001 Jun; 12(3):197-202. PubMed ID: 11380561
[TBL] [Abstract][Full Text] [Related]
12. Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer: a pilot study.
Makris A; Powles TJ; Allred DC; Ashley SE; Trott PA; Ormerod MG; Titley JC; Dowsett M
Breast Cancer Res Treat; 1999 Jan; 53(1):51-9. PubMed ID: 10206072
[TBL] [Abstract][Full Text] [Related]
13. Bcl-2 expression on fine-needle aspirates from primary breast carcinoma: correlation with other biologic factors.
Bozzetti C; Nizzoli R; Naldi N; Guazzi A; Camisa R; Bella MA; Cocconi G
Cancer; 1999 Aug; 87(4):224-30. PubMed ID: 10455211
[TBL] [Abstract][Full Text] [Related]
14. Positive immunohistochemical expression of bcl-2 in hormone-independent breast carcinomas is associated with a greater lymph node involvement and poor outcome.
Ruibal Á; Aguiar P; Del Río MC; Menéndez P; Arias JI; Herranz M
Med Oncol; 2014 Aug; 31(8):105. PubMed ID: 25008065
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer.
Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL
Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569
[TBL] [Abstract][Full Text] [Related]
16. p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer.
Berns EM; Klijn JG; van Putten WL; de Witte HH; Look MP; Meijer-van Gelder ME; Willman K; Portengen H; Benraad TJ; Foekens JA
J Clin Oncol; 1998 Jan; 16(1):121-7. PubMed ID: 9440732
[TBL] [Abstract][Full Text] [Related]
17. Multiple expression patterns of biopathological markers in primary invasive breast carcinoma: a useful tool for elucidating its biological behaviour.
Ceccarelli C; Santini D; Chieco P; Taffurelli M; Marrano D; Mancini AM
Ann Oncol; 1995 Mar; 6(3):275-82. PubMed ID: 7612493
[TBL] [Abstract][Full Text] [Related]
18. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
19. Tumor growth fraction, expression of estrogen and progesterone receptors, p53, bcl-2 and cathepsin D activity in primary ductal invasive breast carcinoma and their axillary lymph node metastases.
Kristek J; Dmitrović B; Kurbel S; Sakić K; Krajinović Z; Blazicević V; Has B; Marjanović K
Coll Antropol; 2007 Dec; 31(4):1043-7. PubMed ID: 18217456
[TBL] [Abstract][Full Text] [Related]
20. Association between tumor size and immunohistochemical expression of Ki-67, p53 and BCL2 in a node-negative breast cancer population selected from a breast cancer screening program.
González-Sistal A; Sánchez AB; Del Rio MC; Arias JI; Herranz M; Ruibal A
Anticancer Res; 2014 Jan; 34(1):269-73. PubMed ID: 24403473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
